Incyte Expands AI Drug Discovery With Genesis
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
Cambridge, Massachusetts, USA, April 21, 2026 In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has...
HONG KONG | April 10, 2026 Insilico Medicine has announced the nomination of ISM6200, a potential best-in-class selective NR3C1...
Hong Kong | March 30, 2026 Strategic AI Collaboration to Accelerate Drug Discovery Insilico Medicine has announced a major...
Hong Kong | March 30, 2026 AI Collaboration Accelerates CNS Drug Discovery Insilico Medicine and Tenacia Biotechnology have announced...
Boston, Massachusetts, March 16, 2026 Manifold Bio, a platform therapeutics company focused on AI-driven drug discovery, announced breakthrough results...
March 3, 2026 Insilico Medicine, a clinical-stage biotechnology company known for its generative artificial intelligence platforms, has launched a...
New Report Maps How AI Prioritizes Pet Nutrition – February 18, 2026 | United States A new analytical report...
